Copyright © 2006 Elsevier Ltd All rights reserved.
Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs)
Received 15 June 2006;
Abstract
A group of 4-(4-methanesulfonylphenyl)-3-phenyl-2(5H)furanones possessing an acetyl, 3-oxobut-1-ynyl, [hydroxyl(or alkoxy)imino]alkyl, [hydroxyl(or alkoxy)imino]alkynyl, and N-alkoxy(or N-phenoxy)carbonyl-N-hydroxy-N-ethylamino substituents at the para-position of the C-3 phenyl ring of rofecoxib were synthesized. This group of compounds was designed for evaluation as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs) that exhibit in vivo anti-inflammatory and analgesic activities. In vitro COX-1/COX-2, and 5-LOX/15-LOX, isozyme inhibition structure–activity relationships identified 3-[4-(1-hydroxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17a) having an optimal combination of COX-2 (COX-2 IC50 = 1.4 μM; COX-2 SI > 71), and 5-LOX and 15 LOX (5-LOX IC50 = 0.28 μM; 15-LOX IC50 = 0.32 μM), inhibitory effects. It was also discovered that 3-[4-(3-hydroxyiminobut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (18a) possesses dual COX-2 (IC50 = 2.7 μM) and 5-LOX (IC50 = 0.30 μM) inhibitor actions. Further in vivo studies employing a rat carrageenan-induced paw edema model showed that the oxime compounds (17a, 18a) were more potent anti-inflammatory agents than the 5-LOX inhibitor caffeic acid, and 15-LOX inhibitor nordihydroguaiaretic acid (NDGA), but less potent than the selective COX-2 inhibitor celecoxib. The results of this investigation showed that incorporation of a para-oxime moiety on the C-3 phenyl ring of rofecoxib provides a suitable template for the design of dual inhibitors of the COX and LOX enzymes.
Keywords: Rofecoxib analogues; 3,4-Diaryl-2(5H)furanones; Anti-inflammatory activity; Oximes; Dual cyclooxygenase and lipoxygenase inhibitors
Article Outline
- 1. Introduction
- 2. Chemistry
- 3. Results and discussion
- 4. Conclusions
- 5. Experimental
- 5.1. Ethyl 4-acetylphenylacetate (6)
- 5.2. Ethyl 4-(1-hydroxy)ethylphenylacetate (7)
- 5.3. 4-(1-Hydroxy)ethylphenylacetic acid (8)
- 5.4. 4-Iodophenylacetic acid (10)
- 5.5. 4-(3-Hydroxybut-1-ynyl)phenylacetic acid (11)
- 5.6. General procedure for the synthesis of 4-(4-methanesulfonylphenyl)-3-(4-substituted-phenyl)-2(5H)furanones (13 and 14)
- 5.6.1. 3-[4-(1-Hydroxy)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (13)
- 5.6.2. 3-[4-(3-Hydroxybut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (14)
- 5.7. General procedure for the synthesis of 3-[4-acetyl and 4-(3-oxobut-1-ynyl)phenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanones (15 and 16)
- 5.7.1. 3-(4-Acetylphenyl)-4-(4-methanesulfonylphenyl)-2(5H)furanone (15)
- 5.7.2. 4-(4-Methanesulfonylphenyl)-3-[4-(3-oxobut-1-ynyl)phenyl]-2(5H)furanone (16)
- 5.8. General procedure for the synthesis of 3-(4-alkyloxyiminoalkylphenyl)-4-(4-methanesulfonylphenyl)-2(5H)furanones (17 and 18)
- 5.8.1. 3-[4-(1-Hydroxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17a)
- 5.8.2. 4-(4-Methanesulfonylphenyl)-3-[4-(1-methoxyimino)ethylphenyl]-2(5H)furanone (17b)
- 5.8.3. 3-[4-(1-Benzyloxyimino)ethylphenyl]-4-(4-methanesulfonylphenyl)-2(5H)furanone (17c)
- 5.8.4. 3-[4-(3-Hydroxyiminobut-1-ynyl)phenyl]-4-(4- methanesulfonylphenyl)-2(5H)furanone (18a)
- 5.8.5. 4-(4-Methanesulfonylphenyl)-3-[4-(3-methoxyiminobut-1-ynyl)phenyl]-2(5H)furanone (18b)
- 5.8.6. 3-[4-(3-Benzyloxyiminobut-1-ynyl)phenyl]-4-(4- methanesulfonylphenyl)-2(5H)furanone (18c)
- 5.9. General procedure for the synthesis of N-alkoxycarbonyl-N-hydroxylamines (20)
- 5.9.1. N-Isopropyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20a)
- 5.9.2. N-Isobutyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20b)
- 5.9.3. N-Phenoxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20c)
- 5.9.4. N-Benzyloxycarbonyl-N-{1-[4-(4-methanesulfonylphenyl)-2(5H)furanon-3-yl]phenyl}ethylhydroxylamine (20d)
- 6. Molecular modeling (docking) study
- 7. In vitro lipoxygenase (LOX) inhibition assays
- 8. In vitro cyclooxygenase (COX) inhibition assay
- 9. Anti-inflammatory assay
- 10. Analgesic assay
- Acknowledgements
- References






E-mail Article
Add to my Quick Links

Cited By in Scopus (1)







